Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 4,708 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Signs and Symptoms, Respiratory Clear all
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

NCT02343458
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
GFF MDI (PT003), FF MDI (PT005), GP MDI (PT001), Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
1,756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
44
States / cities
Andalusia, Alabama • Birmingham, Alabama • Foley, Alabama + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 17, 2026, 8:11 PM EDT
Recruiting Phase 1 Interventional

A Study of NX-1607 in Adults With Advanced Malignancies

NCT05107674
View directory record Official record
Conditions
Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma
Interventions
NX-1607, Paclitaxel
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 17, 2026, 8:11 PM EDT
Completed Phase 2 Interventional

Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

NCT04780984
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tiotropium bromide inhalation solution, Placebo
Drug
Lead sponsor
Nephron Pharmaceuticals Corporation
Industry
Eligibility
40 Years to 80 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Rock Hill, South Carolina
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 17, 2026, 8:11 PM EDT
Completed Phase 2 Interventional

Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease

NCT03038178
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous, Mycobacteria, Atypical
Interventions
LAI plus multi-drug regimen
Drug
Lead sponsor
Kevin Winthrop
Other
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Portland, Oregon • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 17, 2026, 8:11 PM EDT
Not yet recruiting Not applicable Interventional

Feasibility, Acceptability, and Safety Trial of Brief, Breath Control-Focused Acceptance and Commitment Therapy in Adults With Chronic Cough

NCT07566117
View directory record Official record
Conditions
Chronic Cough
Interventions
Acceptance and Commitment Therapy (ACT)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 17, 2026, 8:11 PM EDT
Completed Phase 4 Interventional Results available

Preventing Depression in People Receiving Mechanical Ventilation in an Intensive Care Unit

NCT00872027
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
25 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 17, 2026, 8:11 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cognitive and Immunologic Profiles of Patients With Olfactory Dysfunction After Smell Training

NCT07681973
View directory record Official record
Conditions
Smell Loss, Chronic Rhinosinusitis (CRS)
Interventions
Smell Training
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 17, 2026, 8:11 PM EDT
Recruiting No phase listed Observational

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

NCT00576069
View directory record Official record
Conditions
Asthma
Interventions
budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol, Prednisone
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
10 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 17, 2026, 8:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Predictors of the Metabolic Effect of Sleep Loss

NCT00965783
View directory record Official record
Conditions
Apnea, Obstructive Sleep Apnea (OSA), Obesity
Interventions
Restriction, Extension
Other
Lead sponsor
University of Chicago
Other
Eligibility
25 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 17, 2026, 8:11 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)

NCT00791102
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
ASP-1001 nasal spray, Placebo for ASP-1001
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Days to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 17, 2026, 8:11 PM EDT
Completed Phase 1 Interventional

Surgery and Intrapleural Docetaxel in Treating Patients With Malignant Pleural Effusion

NCT00114205
View directory record Official record
Conditions
Metastatic Cancer
Interventions
docetaxel, therapeutic thoracoscopy
Drug · Procedure
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2010 · Synced Oct 17, 2026, 8:11 PM EDT
Active, not recruiting Phase 1 Interventional

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

NCT05277051
View directory record Official record
Conditions
Neoplasms
Interventions
Remzistotug, Dostarlimab, Belrestotug, Nelistotug, GSK5764227
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
San Francisco, California • Charlotte, North Carolina • Oklahoma City, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 17, 2026, 8:11 PM EDT
Completed Phase 4 Interventional Results available

Pain Control Following Sinus Surgery

NCT03783702
View directory record Official record
Conditions
Sinusitis, Opioid Use, Opioid Abuse, Narcotic Use, Otolaryngologic Disease, Postoperative Pain, Pain
Interventions
OxyCODONE 5 Mg (milligram) Oral Tablet, Ibuprofen 600 Mg (milligram) Oral Tablet, Acetaminophen 650 MG (milligram) Oral Tablet
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Stanford, California • Evanston, Illinois • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 17, 2026, 8:11 PM EDT
Active, not recruiting Phase 2 Interventional

A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

NCT06748053
View directory record Official record
Conditions
Asthma
Interventions
GSK5784283, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
51
States / cities
Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 17, 2026, 8:11 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT01279057
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals), Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray, Placebo
Drug
Lead sponsor
Sandoz
Industry
Eligibility
12 Years and older
Enrollment
727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
7
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 17, 2026, 8:11 PM EDT
Completed Phase 2 Interventional Results available

Trial of AD036 in Obstructive Sleep Apnea

NCT03845023
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
AD036 Dose 1, AD036 Dose 2, AD036 Dose 3, Placebo
Drug
Lead sponsor
Apnimed
Industry
Eligibility
25 Years to 70 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
12
States / cities
Glendale, Arizona • Little Rock, Arkansas • Redwood City, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 17, 2026, 8:11 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

AIH for Spinal Cord Repair

NCT03780829
View directory record Official record
Conditions
SCI
Interventions
hypoxia, sham hypoxia, D-cycloserine, sham-NMDA agonist, exercise training
Behavioral · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 17, 2026, 8:11 PM EDT
Completed No phase listed Observational

Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure

NCT04999995
View directory record Official record
Conditions
Heart Failure, Dyspnea; Cardiac
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 17, 2026, 8:11 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Buspirone in Reducing Shortness of Breath in Patients With Cancer

NCT00053846
View directory record Official record
Conditions
Dyspnea, Pulmonary Complications, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
buspirone hydrochloride, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 120 Years
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
15
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Oct 17, 2026, 8:11 PM EDT
Completed Not applicable Interventional Results available

Innovation in Pulmonary Rehabilitation

NCT00123422
View directory record Official record
Conditions
Pulmonary Disease, Pulmonary Emphysema
Interventions
Breathing retraining, Heliox, Exercise
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
40 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 17, 2026, 8:11 PM EDT
Completed Phase 1Phase 2 Interventional

Expiratory Muscle Training in Patients With Parkinson's Disease

NCT00843739
View directory record Official record
Conditions
Parkinson's Disease
Interventions
EMST - Active Treatment, sham EMST
Device
Lead sponsor
University of Florida
Other
Eligibility
35 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Oct 17, 2026, 8:11 PM EDT
Completed No phase listed Observational

FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)

NCT02922751
View directory record Official record
Conditions
Biliary Atresia, Alagille Syndrome, Alpha1 Anti-Trypsin Deficiency, Portal Hypertension, Liver Fibrosis, Cholestasis
Interventions
Liver Stiffness Measurement (LSM)
Other
Lead sponsor
Arbor Research Collaborative for Health
Other
Eligibility
Up to 21 Years
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 17, 2026, 8:11 PM EDT
Completed Not applicable Interventional Results available

A Comparison of Methods of Discontinuing Nasal CPAP in Premature Infants <30 Weeks Gestation

NCT03292562
View directory record Official record
Conditions
Apnea of Prematurity, Respiratory Distress Syndrome
Interventions
Discontinue NCPAP after weaning pressures, Discontinue NCPAP without weaning pressures
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Not listed
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 17, 2026, 8:11 PM EDT
Withdrawn Phase 3 Interventional

A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy

NCT00891761
View directory record Official record
Conditions
Cancer, Chemotherapy-Induced Nausea and Vomiting, Nausea and Vomiting, Solid Tumor Cancer
Interventions
Dexamethasone, IV casopitant (placebo), IV casopitant (active), Ondansetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Robbinsdale, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 17, 2026, 8:11 PM EDT